Shots:
- The US FDA has granted approval to Lymphir for treating chronic r/r CTCL in patients treated with at least one prior systemic therapy, with its introduction anticipated within the next 5mos.
- The approval was based on P-III (Study 302) trial assessing the safety & efficacy of Lymphir (9mcg/kg, IV) among patients (n=69) with r/r CTCL (stage I to IV)
- The study showed an ORR of 36.2%, CR in 8.7%, median TTE of 1.41mos. in ~70% post 1–2 cycles of treatment and DoR of at least 6mos. in 52%. 84.4% of them showed reduced skin tumor burden, with 12.5% achieving complete skin clearance. Pruritus improved in 31.7% of patients without any cumulative toxicity
Ref: PRNewswire | Image: Citius Pharmaceuticals| Press Release
Related News:- Servier Reports the US FDA’s Approval of Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
